Format

Send to

Choose Destination
Mol Ther. 2016 Feb;24(2):240-250. doi: 10.1038/mt.2015.176. Epub 2015 Sep 21.

AAV6-mediated Cardiac-specific Overexpression of Ribonucleotide Reductase Enhances Myocardial Contractility.

Author information

1
Mitochondria and Metabolism Center, University of Washington, Seattle, Washington, USA.
2
Department of Neurology, University of Washington, Seattle, Washington, USA.
3
Department of Bioengineering, University of Washington, Seattle, Washington, USA.
4
Division of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA.
5
Department of Biochemistry, University of Washington, Seattle, Washington, USA.
6
Department of Pathology, University of Washington, Seattle, Washington, USA.
7
Department of Bioengineering, University of Washington, Seattle, Washington, USA; Division of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA; Department of Pathology, University of Washington, Seattle, Washington, USA; Center for Cardiovascular Biology, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, Washington, USA.
8
BEAT Biotherapeutics Corp., Seattle, Washington, USA. Electronic address: gmahairas@comcast.net.
9
Department of Bioengineering, University of Washington, Seattle, Washington, USA; Center for Cardiovascular Biology, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, Washington, USA. Electronic address: mregnier@uw.edu.

Abstract

Impaired systolic function, resulting from acute injury or congenital defects, leads to cardiac complications and heart failure. Current therapies slow disease progression but do not rescue cardiac function. We previously reported that elevating the cellular 2 deoxy-ATP (dATP) pool in transgenic mice via increased expression of ribonucleotide reductase (RNR), the enzyme that catalyzes deoxy-nucleotide production, increases myosin-actin interaction and enhances cardiac muscle contractility. For the current studies, we initially injected wild-type mice retro-orbitally with a mixture of adeno-associated virus serotype-6 (rAAV6) containing a miniaturized cardiac-specific regulatory cassette (cTnT(455)) composed of enhancer and promotor portions of the human cardiac troponin T gene (TNNT2) ligated to rat cDNAs encoding either the Rrm1 or Rrm2 subunit. Subsequent studies optimized the system by creating a tandem human RRM1-RRM2 cDNA with a P2A self-cleaving peptide site between the subunits. Both rat and human Rrm1/Rrm2 cDNAs resulted in RNR enzyme overexpression exclusively in the heart and led to a significant elevation of left ventricular (LV) function in normal mice and infarcted rats, measured by echocardiography or isolated heart perfusions, without adverse cardiac remodeling. Our study suggests that increasing RNR levels via rAAV-mediated cardiac-specific expression provide a novel gene therapy approach to potentially enhance cardiac systolic function in animal models and patients with heart failure.

PMID:
26388461
PMCID:
PMC4817808
DOI:
10.1038/mt.2015.176
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center